Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
The history of the oxazaphosphorine cytostatics.
Multiple sclerosis.
CNS myelin wrapping is driven by actin disassembly.
White matter astrocytes in health and disease.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Fingolimod modulates microglial activation to augment markers of remyelination.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Demyelination affects temporal aspects of perception: An optic neuritis study.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Considering the influence of stimulation parameters on the effect of conventional and high-definition transcranial direct current stimulation.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Pages
« first
‹ previous
…
92
93
94
95
96
97
98
99
100
…
next ›
last »